)

Aspen Pharmacare Holdings (APN) investor relations material
Aspen Pharmacare Holdings H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Commercial pharma delivered strong, sustained double-digit CER growth across all segments and regions, especially in Africa, Middle East, and Latin America, with notable momentum in China and successful Latam acquisition.
Faced extreme macroeconomic turbulence, including currency volatility and regulatory changes, requiring a shift in strategy and operational focus.
Loss of a major manufacturing contract and retrospective global tax changes significantly impacted EBITDA, net earnings, and led to increased impairments.
Strategic focus now on sustaining commercial pharma momentum, restructuring manufacturing, and unlocking value from assets.
Operating cash conversion rate reached 147%, a five-year high, supported by improved working capital management.
Financial highlights
Group revenue at ZAR43bn, down 3% reported but up 1% at constant exchange rates; Commercial Pharma revenue up 10% CER, Manufacturing down 19% CER.
Normalized EBITDA at ZAR9.6bn, down 8% year-over-year at CER, mainly due to the contract loss.
Normalized headline earnings per share fell 22% at CER, with higher interest and tax costs.
Gross profit margin improved to 44.1% from 42.6%, driven by higher commercial pharma mix.
Net working capital as % of revenue increased to 47%, above the 45% target, mainly due to contract loss.
Outlook and guidance
Double-digit normalized HEPS growth expected for FY26 at constant currency, supported by improved EBITDA margin.
H1 2026 CER NHEPS to be below H1 2025, but strong double-digit growth expected in H2 2026.
Mid-single digit commercial pharma revenue growth forecast, with higher EBITDA and gross profit margin improvements.
Manufacturing EBITDA targeted to return to positive by FY27, with no GLP-1 income included in current guidance.
CapEx to decline to ZAR3.8bn in FY26, with further reductions planned to align with depreciation by FY27/28; leverage ratio projected to fall below 3x.
Next Aspen Pharmacare Holdings earnings date

Next Aspen Pharmacare Holdings earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage